Catalyst
Slingshot members are tracking this event:
Capricor Therapeutics Announces the First Patient with Duchenne Muscular Dystrophy-Related Cardiomyopathy Treated with CAP-1002 in the HOPE-Duchenne Phase I/II Clinical Trial
- Source Link:
- http://www.irdirect.net/pr/release/id/1750739
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| CAPR | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 22, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Duchenne Muscular Dystrophy, Dmd, Cardiomyopathy, Cap-1002, Hope-duchenne Phase I/ii Trial, Cardiosphere-derived Stem Cell, Allogeneic
